Presentation Transcript

1. MERS-CoV: the disease

   Republic of Lebanon Ministry of Public Health Epidemiological Surveillance Program May 2014
2. Sources WHO: www.who.int CDC: www.cdc.gov ECDC: www.ecdc.europa.eu
3. Outline Appellation First cases Reservoir Modes of transmission Incubation period Clinical presentation Case management
4. Appellation Scientific appellation: The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) By the Coronavirus Study Group of the International Committee on Taxonomy of Viruses Reference: De Groot RJ, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. J Virol. Published ahead of print 15 May 2013. doi:10.1128/JVI.01244-13.
5. Classical coronavirus Coronaviruses Large family of viruses that cause a range of illnesses in humans Viruses also cause a number of animal diseases In Humans: Usually: common cold Rarely, severe diseases as: Severe Acute Respiratory Syndrome (SARS) MERS-CoV
6. First cases On 22 September 2012, the UK informed WHO of a case of acute respiratory syndrome with renal failure with travel history to Saudi Arabia and Qatar. The case: previously healthy, 49 year-old male, Qatari, with travel history to Saudi Arabia, On 3 September: presented symptoms On 7 September: admission to ICU in Doha, Qatar On 11 September: transfer to UK (by air ambulance). The Health Protection Agency of the UK (HPA) confirmed the presence of a novel coronavirus The HPA compared the clinical sample with a virus sequenced previously by the Erasmus University Medical Centre, Netherlands: Isolate obtained from lung tissue of a fatal case earlier this year in a 60 year-old Saudi national This comparison indicated 99.5% identity, with one nucleotide mismatch over the regions compared.
7. Jordan cluster On 30 November 2012: two cases from Jordan were added. The fatal cases occurred in April 2012. At that time, a number of severe pneumonia cases occurred in the country – cluster in hospital setting. On 24 April 2012: samples had tested negative for known coronaviruses and other respiratory viruses. In October 2012: stored samples from the cluster of April 2012 were sent by MOH Jordan to NAMRU-3. In November 2012: NAMRU-3 confirmed two cases of infection with the novel coronavirus.
8. Reservoir The full picture on the source is not yet clear. Camels: Camels are a likely source of infection in humans. Strains of MERS‐CoVin camels across Africa and the Middle East. Human and camel genetic sequence data demonstrate a close link between the virus found in camels and that found in people. Other reservoirs may exist.
9. Modes of transmission Different modes of transmission are occurring Zoonotic transmission from animals, camels, to humans Thus far: primary cases have steadily been reported since April 2013 with recent increase in March and April 2014 Human-to-human transmission: Very little human-to-human transmission is occurring among family members in household settings Nosocomial transmission is occurring health care workers and between patients resulting in large health care setting outbreaks Transmission via environmental or fomite contamination Experimental studies of virus persistence on surfaces and at different environmental conditions show that MERS-CoV can be transmitted via contact or fomite Source: WHO
10. Incubation period Usually 5 days Range: 2-14 days Source: Hospital Outbreak of Middle East Respiratory SyndromeCoronavirus - n engl j med 369;5 nejm.org august 1, 2013
11. Symptoms A typical case of MERS consists of Acute respiratory infection: Fever Cough Shortness of breath / Dyspnea Pneumonia is a common finding on examination Gastrointestinal symptoms: diarrhoea may be reported Severe illness: Respiratory failure requiring mechanical ventilation and support in intensive‐care unit. Organ failure: renal failure, septic shock. Approximately 27% of patients with MERS have died. More severe disease is observed in people with weakened immune systems, older people, and those with such chronic diseases as diabetes, cancer, and chronic lung disease.
12. Symptoms Source: Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Abdullah AssiriMD,Jaffar A Al-TawfiqFACP,Abdullah A Al-RabeeahFRCS,Fahad A Al-RabiahMD,Sami Al-HajjarMD,Ali Al-BarrakMD,HeshamFlembanMD,Wafa N Al-Nassir MD,Hanan H BalkhyMD,Rafat F Al-Hakeem MD,Hatem Q MakhdoomPhD,ProfAlimuddin I ZumlaFRCP,ProfZiad A MemishFRCP. The Lancet Infectious Diseases - 1 September 2013 ( Vol. 13, Issue 9, Pages 752-761 ). DOI: 10.1016/S1473-3099(13)70204-4
13. Para-clinical tests Source: Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Abdullah AssiriMD,Jaffar A Al-TawfiqFACP,Abdullah A Al-RabeeahFRCS,Fahad A Al-RabiahMD,Sami Al-HajjarMD,Ali Al-BarrakMD,HeshamFlembanMD,Wafa N Al-Nassir MD,Hanan H BalkhyMD,Rafat F Al-Hakeem MD,Hatem Q MakhdoomPhD,ProfAlimuddin I ZumlaFRCP,ProfZiad A MemishFRCP. The Lancet Infectious Diseases - 1 September 2013 ( Vol. 13, Issue 9, Pages 752-761 ). DOI: 10.1016/S1473-3099(13)70204-4
14. Underlying medical conditions Source: Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Abdullah AssiriMD,Jaffar A Al-TawfiqFACP,Abdullah A Al-RabeeahFRCS,Fahad A Al-RabiahMD,Sami Al-HajjarMD,Ali Al-BarrakMD,HeshamFlembanMD,Wafa N Al-Nassir MD,Hanan H BalkhyMD,Rafat F Al-Hakeem MD,Hatem Q MakhdoomPhD,ProfAlimuddin I ZumlaFRCP,ProfZiad A MemishFRCP. The Lancet Infectious Diseases - 1 September 2013 ( Vol. 13, Issue 9, Pages 752-761 ). DOI: 10.1016/S1473-3099(13)70204-4
15. Pulmonary picture Source: Family Cluster of Middle East Respiratory Syndrome Coronavirus Infections. Ziad A. Memish, M.D., Alimuddin I. Zumla, M.D., Ph.D., Rafat F. Al-Hakeem, M.D., Abdullah A. Al-Rabeeah, M.D., and Gwen M. Stephens, M.D.
16. Example of case Source: Family Cluster of Middle East Respiratory Syndrome Coronavirus Infections. Ziad A. Memish, M.D., Alimuddin I. Zumla, M.D., Ph.D., Rafat F. Al-Hakeem, M.D., Abdullah A. Al-Rabeeah, M.D., and Gwen M. Stephens. n engl j med 368;26 nejm.org june 27, 2013
17. Example of case Source: Family Cluster of Middle East Respiratory Syndrome Coronavirus Infections. Ziad A. Memish, M.D., Alimuddin I. Zumla, M.D., Ph.D., Rafat F. Al-Hakeem, M.D., Abdullah A. Al-Rabeeah, M.D., and Gwen M. Stephens. n engl j med 368;26 nejm.org june 27, 2013
18. Case management:Early recognition and management Recognize severe manifestations of acute respiratory infections Initiate infection prevention and control measures Give supplemental oxygen therapy to patients with SARI Collect respiratory and other specimens for laboratory testing Give empiric antimicrobials to treat suspected pathogens, including community-acquired pathogens Use conservative fluid management in patients with SARI when there is no evidence of shock Closely monitor patients with SARI for signs of clinical deterioration, such as severe respiratory distress/respiratory failure or tissue hypoperfusion/shock, and apply supportive care interventions Source: WHO
19. Case management:Management of severe respiratory distress, hypoxemia and ARDS Recognize severe cases, when severe respiratory distress may not be sufficiently treated by oxygen alone, even when administered at high flow rates Wherever available, and when staff members are trained, mechanical ventilation should be instituted early in patients with increased work of breathing or hypoxemia that persists despite high-flow oxygen therapy Consider NIV if local expertise is available, when immunosuppression is also present, or in cases of mild ARDS without impaired consciousness or cardiovascular failure If equipment is available and staff are trained, proceed with endotracheal intubation to deliver invasive mechanical ventilation Use a lung-protective ventilation strategy (LPV) for patients with ARDS In patients with severe ARDS, consider adjunctive therapeutics early, especially if failing to reach LPV targets Use a conservative fluid management strategy for ARDS patients who are not in shock to shorten the duration of mechanical ventilation (18) Source: WHO
20. Case management: infection control Source: WHO
21. Case management: infection control Source: WHO
22. Case management: infection control Source: WHO